Dr. Ramchandren joins Lee Swanson to discuss the changing treatment for Hodgkin lymphoma patients. From management of side effects to new line treatments, they discuss how patients can best discuss these changes with their doctors.
Published:
On location in San Diego, CA, Patient Power founders Andrew and Esther Schorr are joined by a panel of experts to discuss research developments announced at ASH 2018. Watch day one of Patient Power’s daily wrap to hear the latest blood cancer-related treatment news.
Published:
Is diversity, gender, age and ethnicity important in clinical trials? Mel Mann, a 20+ year CML survivor and a a highly respected leader in the field of clinical oncology weigh in.
Published:
A common question patients have when considering a clinical trial is “will I be a guinea pig?” Meet Reina Weiner, a four-time clinical trial participant, as she shares her experience navigating the trial process, patient consent, safety, risks, family issues and more.
Published:
Lazarex chairman Dana Dornsife says that there’s a “48 percent failure rate of clinical trials, and it's not because the drug didn't work.” Why do some medicines never make it to market? Watch now to find out.
Published:
Which clinical trial is the best choice for you? Watch now to hear Dr. Mike Thompson and patient advocate Jim Omel discuss factors to consider when weighing your options and share tips for patients trying to prioritize different trials.
Published:
Myeloma survivor Reina Weiner and Lazarex chairman Dana Dornsife discuss ways patients can learn about new clinical trial opportunities and share resources to help alleviate the financial burden.
Published:
Many patients wonder; how safe are clinical trials? How transparent is the data from clinical research? Tune in to hear Dr. Mike Thompson and Jim Omel discuss clinical trial care and how the efficacy of new cancer treatments is determined.
Published:
Eligibility criteria determines who can and cannot participate in a clinical trial. Do today’s studies reflect the actual patient population? Why is inclusion so narrow in some cases? Watch now to hear from Dr. Mike Thompson and Jim Omel.
Published:
